BOLT
Price
$6.26Alerts
Change
-$0.04 (-0.63%)
Updated
Nov 11 closing price
Capitalization
12.6M
139 days until earnings call
Intraday BUY SELL Signals
KRRO
Price
$14.41Alerts
Change
-$1.32 (-8.39%)
Updated
Nov 11 closing price
Capitalization
217.2M
138 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BOLT vs KRRO

BOLT vs KRRO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BOLT vs. KRRO commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLT is a Hold and KRRO is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BOLT with price predictions
Nov 11, 2026

BOLT in downward trend: price may drop because broke its higher Bollinger Band on October 23, 2026

BOLT broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 34 similar instances where the stock broke above the upper band. In 32 of the 34 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BOLT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 9 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BOLT as a result. In 94 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for BOLT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 63 of 77 cases where BOLT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

BOLT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BOLT crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

The 50-day moving average for BOLT moved above the 200-day moving average on November 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +61.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BOLT advanced for three days, in 156 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 78 of 92 cases where BOLT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. BOLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.997) is normal, around the industry mean (3.498). P/E Ratio (-0.396) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.355) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for KRRO with price predictions
Nov 11, 2026

Momentum Indicator for KRRO turns positive, indicating new upward trend

KRRO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 70 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for KRRO just turned positive on October 20, 2026. Looking at past instances where KRRO's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.

KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

The Aroon Indicator entered an Uptrend today. In 110 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where KRRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.

The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

KRRO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.498). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
KRRO: Fundamental Ratings
KRRO
OUTLOOK RATING
1..100
45
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
79
SEASONALITY SCORE
1..100
13

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BOLTKRRO
RSI
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
82%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend about 1 month ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
87%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BOLT: $6.30 vs. KRRO: $15.73)
Brand notoriety: BOLT and KRRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BOLT: 38% vs. KRRO: 78%
Market capitalization -- BOLT: $12.6M vs. KRRO: $217.2M
BOLT [@Biotechnology] is valued at $12.6M. KRRO’s [@Biotechnology] market capitalization is $217.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BOLT’s FA Score shows that 0 FA rating(s) are green while KRRO’s FA Score has 0 green FA rating(s).

  • BOLT’s FA Score: 0 green, 5 red.
  • KRRO’s FA Score: 0 green, 5 red.
According to our system of comparison, both BOLT and KRRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BOLT’s TA Score shows that 6 TA indicator(s) are bullish while KRRO’s TA Score has 5 bullish TA indicator(s).

  • BOLT’s TA Score: 6 bullish, 4 bearish.
  • KRRO’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, BOLT is a better buy in the short-term than KRRO.

Price Growth

BOLT (@Biotechnology) experienced а -4.11% price change this week, while KRRO (@Biotechnology) price change was -0.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

BOLT is expected to report earnings on Nov 11, 2026.

KRRO is expected to report earnings on Mar 30, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BOLT and

Correlation & Price change

A.I.dvisor tells us that BOLT and XENE have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BOLT and XENE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLT
1D Price
Change %
BOLT100%
-0.63%
XENE - BOLT
31%
Poorly correlated
+1.72%
ARRY - BOLT
30%
Poorly correlated
+9.94%
KRRO - BOLT
29%
Poorly correlated
-8.39%
SPRO - BOLT
28%
Poorly correlated
+0.99%
XBIO - BOLT
27%
Poorly correlated
+2.22%
More

KRRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRRO has been loosely correlated with MGNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if KRRO jumps, then MGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRRO
1D Price
Change %
KRRO100%
-8.39%
MGNX - KRRO
45%
Loosely correlated
-4.13%
TRDA - KRRO
43%
Loosely correlated
+3.62%
RLAY - KRRO
42%
Loosely correlated
-1.10%
NRIX - KRRO
37%
Loosely correlated
+2.83%
ANRO - KRRO
37%
Loosely correlated
+8.88%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MEDS0.950.06
+6.34%
DataMeds AI Inc
GMAB53.87-0.20
-0.37%
Genmab A/S ADS
DORM134.55-1.25
-0.92%
Dorman Products
SBFG28.82-0.29
-1.00%
SB Financial Group
VRTS129.95-1.76
-1.34%
Virtus Investment Partners